nodes	percent_of_prediction	percent_of_DWPC	metapath
Glycine—Pulmonary congestion—Imiquimod—skin cancer	0.0248	0.0896	CcSEcCtD
Glycine—Respiratory tract congestion—Imiquimod—skin cancer	0.0205	0.0741	CcSEcCtD
Glycine—SLC32A1—Synaptic Vesicle Pathway—SYP—skin cancer	0.0186	0.0942	CbGpPWpGaD
Glycine—GARS—nerve—skin cancer	0.0177	0.0337	CbGeAlD
Glycine—GRIN2C—nerve—skin cancer	0.0174	0.0331	CbGeAlD
Glycine—GARS—hair follicle—skin cancer	0.0148	0.0282	CbGeAlD
Glycine—GATM—hair follicle—skin cancer	0.0141	0.0268	CbGeAlD
Glycine—GLDC—nipple—skin cancer	0.0139	0.0264	CbGeAlD
Glycine—PIPOX—nipple—skin cancer	0.013	0.0247	CbGeAlD
Glycine—GCAT—nipple—skin cancer	0.0126	0.0239	CbGeAlD
Glycine—ALAS1—FOXA2 and FOXA3 transcription factor networks—NKX2-1—skin cancer	0.0122	0.0618	CbGpPWpGaD
Glycine—GRIN2A—nerve—skin cancer	0.012	0.0229	CbGeAlD
Glycine—SLC6A5—head—skin cancer	0.0113	0.0216	CbGeAlD
Glycine—ALAS1—nipple—skin cancer	0.011	0.021	CbGeAlD
Glycine—Hyponatraemia—Vismodegib—skin cancer	0.0104	0.0374	CcSEcCtD
Glycine—GARS—nipple—skin cancer	0.01	0.0191	CbGeAlD
Glycine—ALAS2—female reproductive system—skin cancer	0.00967	0.0184	CbGeAlD
Glycine—GLYATL2—head—skin cancer	0.00964	0.0184	CbGeAlD
Glycine—Dehydration—Vismodegib—skin cancer	0.0096	0.0347	CcSEcCtD
Glycine—GPR18—lymphoid tissue—skin cancer	0.00928	0.0177	CbGeAlD
Glycine—GPR18—female reproductive system—skin cancer	0.00895	0.017	CbGeAlD
Glycine—SLC32A1—head—skin cancer	0.0089	0.0169	CbGeAlD
Glycine—GSS—hair follicle—skin cancer	0.00881	0.0168	CbGeAlD
Glycine—SHMT2—nipple—skin cancer	0.00874	0.0166	CbGeAlD
Glycine—SLC6A9—head—skin cancer	0.00859	0.0164	CbGeAlD
Glycine—GLRA3—head—skin cancer	0.00859	0.0164	CbGeAlD
Glycine—Cardiovascular disorder—Imiquimod—skin cancer	0.00853	0.0308	CcSEcCtD
Glycine—GCSH—female reproductive system—skin cancer	0.00838	0.016	CbGeAlD
Glycine—GLDC—mammalian vulva—skin cancer	0.00811	0.0154	CbGeAlD
Glycine—GCAT—skin of body—skin cancer	0.00806	0.0153	CbGeAlD
Glycine—SHMT1—nipple—skin cancer	0.00795	0.0151	CbGeAlD
Glycine—SLC32A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC12A2—skin cancer	0.00765	0.0387	CbGpPWpGaD
Glycine—PIPOX—mammalian vulva—skin cancer	0.00757	0.0144	CbGeAlD
Glycine—AGXT2—female reproductive system—skin cancer	0.00744	0.0142	CbGeAlD
Glycine—GCAT—mammalian vulva—skin cancer	0.00735	0.014	CbGeAlD
Glycine—GNMT—female reproductive system—skin cancer	0.00733	0.014	CbGeAlD
Glycine—GARS—connective tissue—skin cancer	0.00712	0.0136	CbGeAlD
Glycine—GCSH—head—skin cancer	0.007	0.0133	CbGeAlD
Glycine—GLDC—female reproductive system—skin cancer	0.00695	0.0132	CbGeAlD
Glycine—Encephalopathy—Fluorouracil—skin cancer	0.00645	0.0233	CcSEcCtD
Glycine—ALAS1—mammalian vulva—skin cancer	0.00644	0.0123	CbGeAlD
Glycine—GARS—skin of body—skin cancer	0.00643	0.0122	CbGeAlD
Glycine—Lung disorder—Temozolomide—skin cancer	0.00635	0.0229	CcSEcCtD
Glycine—ALAS1—PPARA activates gene expression—PLIN2—skin cancer	0.00619	0.0313	CbGpPWpGaD
Glycine—ALAS1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PLIN2—skin cancer	0.00606	0.0307	CbGpPWpGaD
Glycine—SLC6A9—lymph node—skin cancer	0.00602	0.0115	CbGeAlD
Glycine—Back pain—Vismodegib—skin cancer	0.00602	0.0217	CcSEcCtD
Glycine—GSS—nipple—skin cancer	0.00597	0.0114	CbGeAlD
Glycine—GLRA2—head—skin cancer	0.00596	0.0113	CbGeAlD
Glycine—GARS—mammalian vulva—skin cancer	0.00586	0.0112	CbGeAlD
Glycine—GLDC—head—skin cancer	0.0058	0.0111	CbGeAlD
Glycine—SHMT2—skin of body—skin cancer	0.00559	0.0107	CbGeAlD
Glycine—ALAS1—female reproductive system—skin cancer	0.00551	0.0105	CbGeAlD
Glycine—PIPOX—head—skin cancer	0.00542	0.0103	CbGeAlD
Glycine—GCAT—head—skin cancer	0.00526	0.01	CbGeAlD
Glycine—GPR18—lymph node—skin cancer	0.00523	0.00997	CbGeAlD
Glycine—GARS—lymphoid tissue—skin cancer	0.00521	0.00991	CbGeAlD
Glycine—Urinary retention—Imiquimod—skin cancer	0.00517	0.0187	CcSEcCtD
Glycine—SHMT2—mammalian vulva—skin cancer	0.0051	0.00971	CbGeAlD
Glycine—GARS—female reproductive system—skin cancer	0.00502	0.00956	CbGeAlD
Glycine—GCSH—lymph node—skin cancer	0.0049	0.00934	CbGeAlD
Glycine—GATM—female reproductive system—skin cancer	0.00477	0.00908	CbGeAlD
Glycine—SHMT1—mammalian vulva—skin cancer	0.00464	0.00884	CbGeAlD
Glycine—ALAS1—head—skin cancer	0.00461	0.00877	CbGeAlD
Glycine—GPR18—GPCRs, Other—SMO—skin cancer	0.00455	0.023	CbGpPWpGaD
Glycine—SHMT2—lymphoid tissue—skin cancer	0.00453	0.00863	CbGeAlD
Glycine—SLC36A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC12A2—skin cancer	0.00439	0.0222	CbGpPWpGaD
Glycine—SLC16A10—nipple—skin cancer	0.00437	0.00833	CbGeAlD
Glycine—SHMT2—female reproductive system—skin cancer	0.00437	0.00832	CbGeAlD
Glycine—Pain—Vismodegib—skin cancer	0.00434	0.0157	CcSEcCtD
Glycine—SLC16A10—neck—skin cancer	0.00433	0.00824	CbGeAlD
Glycine—GARS—head—skin cancer	0.0042	0.00799	CbGeAlD
Glycine—ALAS1—Fatty acid, triacylglycerol, and ketone body metabolism—PLIN2—skin cancer	0.00418	0.0211	CbGpPWpGaD
Glycine—GRIN2C—head—skin cancer	0.00413	0.00786	CbGeAlD
Glycine—SHMT1—lymphoid tissue—skin cancer	0.00412	0.00785	CbGeAlD
Glycine—GLDC—lymph node—skin cancer	0.00406	0.00774	CbGeAlD
Glycine—SLC6A5—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.00402	0.0203	CbGpPWpGaD
Glycine—SLC6A9—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.00402	0.0203	CbGpPWpGaD
Glycine—GATM—head—skin cancer	0.00398	0.00758	CbGeAlD
Glycine—SHMT1—female reproductive system—skin cancer	0.00398	0.00757	CbGeAlD
Glycine—Chills—Vemurafenib—skin cancer	0.00396	0.0143	CcSEcCtD
Glycine—GSS—skin of body—skin cancer	0.00382	0.00728	CbGeAlD
Glycine—Coma—Fluorouracil—skin cancer	0.00378	0.0136	CcSEcCtD
Glycine—Rhinitis—Imiquimod—skin cancer	0.00377	0.0136	CcSEcCtD
Glycine—Thrombophlebitis—Temozolomide—skin cancer	0.00377	0.0136	CcSEcCtD
Glycine—Back pain—Vemurafenib—skin cancer	0.00372	0.0134	CcSEcCtD
Glycine—GCAT—lymph node—skin cancer	0.00368	0.00701	CbGeAlD
Glycine—SHMT2—head—skin cancer	0.00365	0.00695	CbGeAlD
Glycine—Visual impairment—Imiquimod—skin cancer	0.00363	0.0131	CcSEcCtD
Glycine—GSS—mammalian vulva—skin cancer	0.00349	0.00664	CbGeAlD
Glycine—Diarrhoea—Vismodegib—skin cancer	0.00347	0.0125	CcSEcCtD
Glycine—Thrombophlebitis—Fluorouracil—skin cancer	0.00347	0.0125	CcSEcCtD
Glycine—Thirst—Temozolomide—skin cancer	0.00343	0.0124	CcSEcCtD
Glycine—GLRB—head—skin cancer	0.00342	0.00651	CbGeAlD
Glycine—SLC32A1—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.00342	0.0173	CbGpPWpGaD
Glycine—SLC36A1—female reproductive system—skin cancer	0.00339	0.00646	CbGeAlD
Glycine—Chills—Imiquimod—skin cancer	0.00338	0.0122	CcSEcCtD
Glycine—SHMT1—head—skin cancer	0.00332	0.00633	CbGeAlD
Glycine—Vomiting—Vismodegib—skin cancer	0.00323	0.0116	CcSEcCtD
Glycine—ALAS1—lymph node—skin cancer	0.00323	0.00614	CbGeAlD
Glycine—Back pain—Imiquimod—skin cancer	0.00317	0.0114	CcSEcCtD
Glycine—Dehydration—Temozolomide—skin cancer	0.00303	0.0109	CcSEcCtD
Glycine—Nausea—Vismodegib—skin cancer	0.00301	0.0109	CcSEcCtD
Glycine—GSS—female reproductive system—skin cancer	0.00299	0.00569	CbGeAlD
Glycine—SLC16A10—epithelium—skin cancer	0.00294	0.00561	CbGeAlD
Glycine—GARS—lymph node—skin cancer	0.00294	0.00559	CbGeAlD
Glycine—Hypotension—Vemurafenib—skin cancer	0.00293	0.0106	CcSEcCtD
Glycine—GPR18—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.00292	0.0148	CbGpPWpGaD
Glycine—GRIN2A—head—skin cancer	0.00285	0.00543	CbGeAlD
Glycine—Convulsion—Imiquimod—skin cancer	0.00284	0.0102	CcSEcCtD
Glycine—SLC36A1—head—skin cancer	0.00283	0.0054	CbGeAlD
Glycine—GATM—lymph node—skin cancer	0.00279	0.00531	CbGeAlD
Glycine—Oedema—Imiquimod—skin cancer	0.00267	0.00965	CcSEcCtD
Glycine—Lightheadedness—Docetaxel—skin cancer	0.00267	0.00965	CcSEcCtD
Glycine—SLC16A10—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC12A2—skin cancer	0.00267	0.0135	CbGpPWpGaD
Glycine—GPR18—GPCR ligand binding—PTCH2—skin cancer	0.00264	0.0133	CbGpPWpGaD
Glycine—Tachycardia—Imiquimod—skin cancer	0.00261	0.00942	CcSEcCtD
Glycine—SHMT2—lymph node—skin cancer	0.00256	0.00487	CbGeAlD
Glycine—SLC16A10—mammalian vulva—skin cancer	0.00255	0.00486	CbGeAlD
Glycine—Angina pectoris—Fluorouracil—skin cancer	0.00253	0.00913	CcSEcCtD
Glycine—GPR18—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.00251	0.0127	CbGpPWpGaD
Glycine—Thrombophlebitis—Docetaxel—skin cancer	0.0025	0.00904	CcSEcCtD
Glycine—GSS—head—skin cancer	0.0025	0.00475	CbGeAlD
Glycine—Chills—Bleomycin—skin cancer	0.0024	0.00866	CcSEcCtD
Glycine—GLRB—lymph node—skin cancer	0.0024	0.00456	CbGeAlD
Glycine—GRIN2C—CREB phosphorylation through the activation of Ras—BRAF—skin cancer	0.00239	0.0121	CbGpPWpGaD
Glycine—SHMT1—lymph node—skin cancer	0.00233	0.00443	CbGeAlD
Glycine—Hypersensitivity—Vemurafenib—skin cancer	0.00231	0.00834	CcSEcCtD
Glycine—Visual disturbance—Docetaxel—skin cancer	0.00229	0.00826	CcSEcCtD
Glycine—Pain—Imiquimod—skin cancer	0.00229	0.00825	CcSEcCtD
Glycine—SLC16A10—lymphoid tissue—skin cancer	0.00227	0.00432	CbGeAlD
Glycine—Chills—Dactinomycin—skin cancer	0.00224	0.00808	CcSEcCtD
Glycine—SLC16A10—female reproductive system—skin cancer	0.00219	0.00417	CbGeAlD
Glycine—Hyponatraemia—Docetaxel—skin cancer	0.00218	0.00786	CcSEcCtD
Glycine—Visual impairment—Temozolomide—skin cancer	0.00217	0.00785	CcSEcCtD
Glycine—Diarrhoea—Vemurafenib—skin cancer	0.00215	0.00774	CcSEcCtD
Glycine—Urticaria—Imiquimod—skin cancer	0.00212	0.00767	CcSEcCtD
Glycine—Rhinitis—Fluorouracil—skin cancer	0.00208	0.00752	CcSEcCtD
Glycine—Dizziness—Vemurafenib—skin cancer	0.00207	0.00748	CcSEcCtD
Glycine—SLC6A5—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.00204	0.0103	CbGpPWpGaD
Glycine—SLC6A9—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.00204	0.0103	CbGpPWpGaD
Glycine—Chills—Temozolomide—skin cancer	0.00202	0.00731	CcSEcCtD
Glycine—Dehydration—Docetaxel—skin cancer	0.00202	0.00728	CcSEcCtD
Glycine—Vomiting—Vemurafenib—skin cancer	0.00199	0.0072	CcSEcCtD
Glycine—SLC36A1—lymph node—skin cancer	0.00198	0.00378	CbGeAlD
Glycine—Hypersensitivity—Imiquimod—skin cancer	0.00197	0.00711	CcSEcCtD
Glycine—GRIN2C—Post NMDA receptor activation events—BRAF—skin cancer	0.00197	0.00994	CbGpPWpGaD
Glycine—SLC36A1—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.00196	0.00993	CbGpPWpGaD
Glycine—BAAT—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	0.00193	0.00975	CbGpPWpGaD
Glycine—GPR18—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.00192	0.00973	CbGpPWpGaD
Glycine—GPR18—GPCR ligand binding—MC1R—skin cancer	0.00191	0.00965	CbGpPWpGaD
Glycine—Oedema—Bleomycin—skin cancer	0.0019	0.00686	CcSEcCtD
Glycine—Back pain—Temozolomide—skin cancer	0.0019	0.00686	CcSEcCtD
Glycine—Nausea—Vemurafenib—skin cancer	0.00186	0.00672	CcSEcCtD
Glycine—Vision blurred—Temozolomide—skin cancer	0.00185	0.00668	CcSEcCtD
Glycine—Diarrhoea—Imiquimod—skin cancer	0.00183	0.0066	CcSEcCtD
Glycine—Angina pectoris—Docetaxel—skin cancer	0.00183	0.00659	CcSEcCtD
Glycine—GRIN2A—CREB phosphorylation through the activation of Ras—BRAF—skin cancer	0.00182	0.00922	CbGpPWpGaD
Glycine—GRIN2C—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—skin cancer	0.00181	0.00915	CbGpPWpGaD
Glycine—Hypotension—Bleomycin—skin cancer	0.00178	0.00641	CcSEcCtD
Glycine—Oedema—Dactinomycin—skin cancer	0.00177	0.0064	CcSEcCtD
Glycine—Dizziness—Imiquimod—skin cancer	0.00177	0.00638	CcSEcCtD
Glycine—Vertigo—Temozolomide—skin cancer	0.00176	0.00637	CcSEcCtD
Glycine—GSS—lymph node—skin cancer	0.00175	0.00333	CbGeAlD
Glycine—SLC32A1—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.00174	0.00878	CbGpPWpGaD
Glycine—GLRA3—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.00174	0.00878	CbGpPWpGaD
Glycine—GLRA2—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.00174	0.00878	CbGpPWpGaD
Glycine—SHMT1—Validated targets of C-MYC transcriptional activation—TERT—skin cancer	0.00172	0.00872	CbGpPWpGaD
Glycine—Vision blurred—Fluorouracil—skin cancer	0.0017	0.00615	CcSEcCtD
Glycine—Convulsion—Temozolomide—skin cancer	0.0017	0.00614	CcSEcCtD
Glycine—Vomiting—Imiquimod—skin cancer	0.0017	0.00614	CcSEcCtD
Glycine—ALAS1—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	0.00166	0.00841	CbGpPWpGaD
Glycine—GPR18—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.00165	0.00833	CbGpPWpGaD
Glycine—GPR18—Signaling Pathways—RHOU—skin cancer	0.00164	0.00828	CbGpPWpGaD
Glycine—Pain—Bleomycin—skin cancer	0.00162	0.00586	CcSEcCtD
Glycine—Oedema—Temozolomide—skin cancer	0.0016	0.00578	CcSEcCtD
Glycine—Nausea—Imiquimod—skin cancer	0.00159	0.00573	CcSEcCtD
Glycine—Convulsion—Fluorouracil—skin cancer	0.00157	0.00566	CcSEcCtD
Glycine—SHMT1—Validated targets of C-MYC transcriptional activation—CDK4—skin cancer	0.00154	0.0078	CbGpPWpGaD
Glycine—GRIN2C—Ras activation uopn Ca2+ infux through NMDA receptor—HRAS—skin cancer	0.00154	0.00779	CbGpPWpGaD
Glycine—Pain—Dactinomycin—skin cancer	0.00152	0.00547	CcSEcCtD
Glycine—Urticaria—Bleomycin—skin cancer	0.00151	0.00545	CcSEcCtD
Glycine—Rhinitis—Docetaxel—skin cancer	0.0015	0.00543	CcSEcCtD
Glycine—GRIN2A—Post NMDA receptor activation events—BRAF—skin cancer	0.0015	0.00759	CbGpPWpGaD
Glycine—Oedema—Fluorouracil—skin cancer	0.00148	0.00533	CcSEcCtD
Glycine—SHMT2—Vitamin B12 Metabolism—IL6—skin cancer	0.00145	0.00731	CbGpPWpGaD
Glycine—Visual impairment—Docetaxel—skin cancer	0.00145	0.00522	CcSEcCtD
Glycine—Tachycardia—Fluorouracil—skin cancer	0.00144	0.0052	CcSEcCtD
Glycine—GLRB—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.00142	0.00716	CbGpPWpGaD
Glycine—Hypersensitivity—Bleomycin—skin cancer	0.0014	0.00505	CcSEcCtD
Glycine—GRIN2A—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—skin cancer	0.00138	0.00699	CbGpPWpGaD
Glycine—Hypotension—Fluorouracil—skin cancer	0.00138	0.00498	CcSEcCtD
Glycine—Pain—Temozolomide—skin cancer	0.00137	0.00495	CcSEcCtD
Glycine—GPR18—GPCR ligand binding—SHH—skin cancer	0.00136	0.00688	CbGpPWpGaD
Glycine—GPR18—Signaling by GPCR—PTCH2—skin cancer	0.00135	0.00685	CbGpPWpGaD
Glycine—Chills—Docetaxel—skin cancer	0.00135	0.00486	CcSEcCtD
Glycine—Hypersensitivity—Dactinomycin—skin cancer	0.00131	0.00471	CcSEcCtD
Glycine—GPR18—GPCR ligand binding—SMO—skin cancer	0.00129	0.00652	CbGpPWpGaD
Glycine—GPR18—GPCR ligand binding—PTCH1—skin cancer	0.00129	0.00652	CbGpPWpGaD
Glycine—SHMT2—Folate Metabolism—TP53—skin cancer	0.00129	0.0065	CbGpPWpGaD
Glycine—SLC16A10—lymph node—skin cancer	0.00128	0.00244	CbGeAlD
Glycine—Urticaria—Temozolomide—skin cancer	0.00127	0.0046	CcSEcCtD
Glycine—Back pain—Docetaxel—skin cancer	0.00126	0.00456	CcSEcCtD
Glycine—Pain—Fluorouracil—skin cancer	0.00126	0.00456	CcSEcCtD
Glycine—GPR18—GPCR ligand binding—PTGER4—skin cancer	0.00125	0.00635	CbGpPWpGaD
Glycine—Diarrhoea—Dactinomycin—skin cancer	0.00121	0.00438	CcSEcCtD
Glycine—Vomiting—Bleomycin—skin cancer	0.00121	0.00436	CcSEcCtD
Glycine—SLC16A10—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.00119	0.00603	CbGpPWpGaD
Glycine—ALAS2—Metabolism—PLIN2—skin cancer	0.00119	0.006	CbGpPWpGaD
Glycine—Hypersensitivity—Temozolomide—skin cancer	0.00118	0.00426	CcSEcCtD
Glycine—SHMT2—Folate Metabolism—IL6—skin cancer	0.00118	0.00595	CbGpPWpGaD
Glycine—GRIN2A—Ras activation uopn Ca2+ infux through NMDA receptor—HRAS—skin cancer	0.00118	0.00594	CbGpPWpGaD
Glycine—Urticaria—Fluorouracil—skin cancer	0.00117	0.00423	CcSEcCtD
Glycine—Convulsion—Docetaxel—skin cancer	0.00113	0.00408	CcSEcCtD
Glycine—Nausea—Bleomycin—skin cancer	0.00113	0.00407	CcSEcCtD
Glycine—Vomiting—Dactinomycin—skin cancer	0.00113	0.00407	CcSEcCtD
Glycine—GLRA1—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.00112	0.00566	CbGpPWpGaD
Glycine—GRIN2C—CREB phosphorylation through the activation of Ras—HRAS—skin cancer	0.0011	0.00555	CbGpPWpGaD
Glycine—Diarrhoea—Temozolomide—skin cancer	0.0011	0.00396	CcSEcCtD
Glycine—Hypersensitivity—Fluorouracil—skin cancer	0.00109	0.00393	CcSEcCtD
Glycine—GPR18—GPCR downstream signaling—MC1R—skin cancer	0.00108	0.00545	CbGpPWpGaD
Glycine—Oedema—Docetaxel—skin cancer	0.00107	0.00385	CcSEcCtD
Glycine—Dizziness—Temozolomide—skin cancer	0.00106	0.00382	CcSEcCtD
Glycine—Nausea—Dactinomycin—skin cancer	0.00105	0.0038	CcSEcCtD
Glycine—SLC32A1—Transmission across Chemical Synapses—BRAF—skin cancer	0.00105	0.00531	CbGpPWpGaD
Glycine—Tachycardia—Docetaxel—skin cancer	0.00104	0.00375	CcSEcCtD
Glycine—SHMT1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—skin cancer	0.00102	0.00516	CbGpPWpGaD
Glycine—Vomiting—Temozolomide—skin cancer	0.00102	0.00368	CcSEcCtD
Glycine—Diarrhoea—Fluorouracil—skin cancer	0.00101	0.00365	CcSEcCtD
Glycine—SLC36A1—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000998	0.00505	CbGpPWpGaD
Glycine—Hypotension—Docetaxel—skin cancer	0.000996	0.00359	CcSEcCtD
Glycine—GPR18—Signaling by GPCR—MC1R—skin cancer	0.000979	0.00495	CbGpPWpGaD
Glycine—Dizziness—Fluorouracil—skin cancer	0.000976	0.00352	CcSEcCtD
Glycine—ALAS2—Metabolism—CSPG4—skin cancer	0.000957	0.00484	CbGpPWpGaD
Glycine—Nausea—Temozolomide—skin cancer	0.000952	0.00344	CcSEcCtD
Glycine—Vomiting—Fluorouracil—skin cancer	0.000939	0.00339	CcSEcCtD
Glycine—Pain—Docetaxel—skin cancer	0.000911	0.00329	CcSEcCtD
Glycine—GRIN2C—Post NMDA receptor activation events—HRAS—skin cancer	0.000904	0.00457	CbGpPWpGaD
Glycine—GATM—Metabolism—PLIN2—skin cancer	0.0009	0.00455	CbGpPWpGaD
Glycine—GLYAT—Metabolism—PLIN2—skin cancer	0.0009	0.00455	CbGpPWpGaD
Glycine—GLYATL1—Metabolism—PLIN2—skin cancer	0.0009	0.00455	CbGpPWpGaD
Glycine—GLYATL2—Metabolism—PLIN2—skin cancer	0.0009	0.00455	CbGpPWpGaD
Glycine—Nausea—Fluorouracil—skin cancer	0.000877	0.00317	CcSEcCtD
Glycine—BAAT—Metabolism—PLIN2—skin cancer	0.000858	0.00434	CbGpPWpGaD
Glycine—GRIN2A—CREB phosphorylation through the activation of Ras—HRAS—skin cancer	0.000838	0.00424	CbGpPWpGaD
Glycine—GRIN2C—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—skin cancer	0.000832	0.00421	CbGpPWpGaD
Glycine—SLC32A1—Neuronal System—BRAF—skin cancer	0.000805	0.00407	CbGpPWpGaD
Glycine—GPR18—Signaling Pathways—PTCH2—skin cancer	0.0008	0.00405	CbGpPWpGaD
Glycine—Hypersensitivity—Docetaxel—skin cancer	0.000785	0.00283	CcSEcCtD
Glycine—AGXT—Metabolism—PLIN2—skin cancer	0.000765	0.00387	CbGpPWpGaD
Glycine—SHMT1—Folate Metabolism—TP53—skin cancer	0.000758	0.00383	CbGpPWpGaD
Glycine—ALAS1—Metabolism—PLIN2—skin cancer	0.000741	0.00375	CbGpPWpGaD
Glycine—Diarrhoea—Docetaxel—skin cancer	0.000729	0.00263	CcSEcCtD
Glycine—GLYATL1—Metabolism—CSPG4—skin cancer	0.000725	0.00367	CbGpPWpGaD
Glycine—GLYATL2—Metabolism—CSPG4—skin cancer	0.000725	0.00367	CbGpPWpGaD
Glycine—GATM—Metabolism—CSPG4—skin cancer	0.000725	0.00367	CbGpPWpGaD
Glycine—GLYAT—Metabolism—CSPG4—skin cancer	0.000725	0.00367	CbGpPWpGaD
Glycine—GPR18—GPCR downstream signaling—PTGER4—skin cancer	0.000709	0.00359	CbGpPWpGaD
Glycine—Dizziness—Docetaxel—skin cancer	0.000705	0.00254	CcSEcCtD
Glycine—GPR18—Signaling by GPCR—SHH—skin cancer	0.000698	0.00353	CbGpPWpGaD
Glycine—SHMT1—Folate Metabolism—IL6—skin cancer	0.000694	0.00351	CbGpPWpGaD
Glycine—BAAT—Metabolism—CSPG4—skin cancer	0.000692	0.0035	CbGpPWpGaD
Glycine—GRIN2A—Post NMDA receptor activation events—HRAS—skin cancer	0.00069	0.00349	CbGpPWpGaD
Glycine—GRIN2C—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—skin cancer	0.000678	0.00343	CbGpPWpGaD
Glycine—Vomiting—Docetaxel—skin cancer	0.000678	0.00245	CcSEcCtD
Glycine—GPR18—Signaling by GPCR—PTCH1—skin cancer	0.000661	0.00334	CbGpPWpGaD
Glycine—GPR18—Signaling by GPCR—SMO—skin cancer	0.000661	0.00334	CbGpPWpGaD
Glycine—SHMT1—Validated targets of C-MYC transcriptional activation—TP53—skin cancer	0.000656	0.00332	CbGpPWpGaD
Glycine—AGXT2—Metabolism—PLIN2—skin cancer	0.00065	0.00329	CbGpPWpGaD
Glycine—ALAS2—Metabolism—ENO2—skin cancer	0.00065	0.00329	CbGpPWpGaD
Glycine—GPR18—Signaling by GPCR—PTGER4—skin cancer	0.000644	0.00326	CbGpPWpGaD
Glycine—GRIN2A—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—skin cancer	0.000635	0.00321	CbGpPWpGaD
Glycine—Nausea—Docetaxel—skin cancer	0.000633	0.00228	CcSEcCtD
Glycine—AGXT—Metabolism—CSPG4—skin cancer	0.000617	0.00312	CbGpPWpGaD
Glycine—SLC16A10—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000606	0.00307	CbGpPWpGaD
Glycine—GPR18—Signaling Pathways—GLI2—skin cancer	0.000606	0.00307	CbGpPWpGaD
Glycine—ALAS1—Metabolism—CSPG4—skin cancer	0.000597	0.00302	CbGpPWpGaD
Glycine—GPR18—Signaling Pathways—MC1R—skin cancer	0.000579	0.00293	CbGpPWpGaD
Glycine—GPR18—Signaling Pathways—GLI1—skin cancer	0.00057	0.00288	CbGpPWpGaD
Glycine—GPR18—Signaling Pathways—SUFU—skin cancer	0.00054	0.00273	CbGpPWpGaD
Glycine—SHMT1—Metabolism—PLIN2—skin cancer	0.00053	0.00268	CbGpPWpGaD
Glycine—AGXT2—Metabolism—CSPG4—skin cancer	0.000524	0.00265	CbGpPWpGaD
Glycine—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—skin cancer	0.000517	0.00262	CbGpPWpGaD
Glycine—GSS—Metabolism—PLIN2—skin cancer	0.000517	0.00261	CbGpPWpGaD
Glycine—GRIN2C—Alzheimers Disease—TP53—skin cancer	0.000515	0.0026	CbGpPWpGaD
Glycine—SHMT1—Disease—CSPG4—skin cancer	0.00051	0.00258	CbGpPWpGaD
Glycine—GRIN2C—Transmission across Chemical Synapses—BRAF—skin cancer	0.00051	0.00258	CbGpPWpGaD
Glycine—GLYAT—Metabolism—ENO2—skin cancer	0.000493	0.00249	CbGpPWpGaD
Glycine—GLYATL2—Metabolism—ENO2—skin cancer	0.000493	0.00249	CbGpPWpGaD
Glycine—GLYATL1—Metabolism—ENO2—skin cancer	0.000493	0.00249	CbGpPWpGaD
Glycine—GATM—Metabolism—ENO2—skin cancer	0.000493	0.00249	CbGpPWpGaD
Glycine—GARS—Gene Expression—ERCC2—skin cancer	0.000486	0.00246	CbGpPWpGaD
Glycine—SLC32A1—Transmission across Chemical Synapses—HRAS—skin cancer	0.000483	0.00244	CbGpPWpGaD
Glycine—BAAT—Metabolism—ENO2—skin cancer	0.00047	0.00238	CbGpPWpGaD
Glycine—SHMT1—Metabolism—CSPG4—skin cancer	0.000427	0.00216	CbGpPWpGaD
Glycine—AGXT—Metabolism—ENO2—skin cancer	0.000419	0.00212	CbGpPWpGaD
Glycine—GSS—Metabolism—CSPG4—skin cancer	0.000417	0.00211	CbGpPWpGaD
Glycine—GPR18—Signaling Pathways—SHH—skin cancer	0.000412	0.00208	CbGpPWpGaD
Glycine—GPR18—Signaling Pathways—RASA1—skin cancer	0.00041	0.00207	CbGpPWpGaD
Glycine—ALAS1—Metabolism—ENO2—skin cancer	0.000406	0.00205	CbGpPWpGaD
Glycine—GRIN2A—Alzheimers Disease—TP53—skin cancer	0.000393	0.00199	CbGpPWpGaD
Glycine—GPR18—Signaling Pathways—PTCH1—skin cancer	0.000391	0.00198	CbGpPWpGaD
Glycine—GPR18—Signaling Pathways—SMO—skin cancer	0.000391	0.00198	CbGpPWpGaD
Glycine—GRIN2C—Neuronal System—BRAF—skin cancer	0.00039	0.00197	CbGpPWpGaD
Glycine—GRIN2A—Transmission across Chemical Synapses—BRAF—skin cancer	0.000389	0.00197	CbGpPWpGaD
Glycine—GPR18—Signaling Pathways—PTGER4—skin cancer	0.00038	0.00192	CbGpPWpGaD
Glycine—ALAS2—Metabolism—ERCC2—skin cancer	0.000378	0.00191	CbGpPWpGaD
Glycine—SLC32A1—Neuronal System—HRAS—skin cancer	0.00037	0.00187	CbGpPWpGaD
Glycine—BAAT—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	0.000368	0.00186	CbGpPWpGaD
Glycine—AGXT2—Metabolism—ENO2—skin cancer	0.000356	0.0018	CbGpPWpGaD
Glycine—SHMT1—Disease—SHH—skin cancer	0.000347	0.00175	CbGpPWpGaD
Glycine—SHMT1—Disease—ENO2—skin cancer	0.000347	0.00175	CbGpPWpGaD
Glycine—GPR18—Signaling Pathways—FOXO4—skin cancer	0.000336	0.0017	CbGpPWpGaD
Glycine—ALAS1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	0.000317	0.00161	CbGpPWpGaD
Glycine—GRIN2C—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—skin cancer	0.000312	0.00158	CbGpPWpGaD
Glycine—GRIN2A—Neuronal System—BRAF—skin cancer	0.000298	0.00151	CbGpPWpGaD
Glycine—SHMT1—Metabolism—ENO2—skin cancer	0.000291	0.00147	CbGpPWpGaD
Glycine—GLYATL2—Metabolism—ERCC2—skin cancer	0.000286	0.00145	CbGpPWpGaD
Glycine—GLYATL1—Metabolism—ERCC2—skin cancer	0.000286	0.00145	CbGpPWpGaD
Glycine—GATM—Metabolism—ERCC2—skin cancer	0.000286	0.00145	CbGpPWpGaD
Glycine—GLYAT—Metabolism—ERCC2—skin cancer	0.000286	0.00145	CbGpPWpGaD
Glycine—GSS—Metabolism—ENO2—skin cancer	0.000283	0.00143	CbGpPWpGaD
Glycine—SHMT1—Disease—FOXO4—skin cancer	0.000283	0.00143	CbGpPWpGaD
Glycine—BAAT—Metabolism—ERCC2—skin cancer	0.000273	0.00138	CbGpPWpGaD
Glycine—AGXT—Metabolism—ERCC2—skin cancer	0.000243	0.00123	CbGpPWpGaD
Glycine—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—skin cancer	0.000238	0.0012	CbGpPWpGaD
Glycine—ALAS1—Metabolism—ERCC2—skin cancer	0.000236	0.00119	CbGpPWpGaD
Glycine—GRIN2C—Transmission across Chemical Synapses—HRAS—skin cancer	0.000234	0.00118	CbGpPWpGaD
Glycine—ALAS2—Metabolism—PTGS2—skin cancer	0.000227	0.00115	CbGpPWpGaD
Glycine—GPR18—Signaling Pathways—TERT—skin cancer	0.000224	0.00113	CbGpPWpGaD
Glycine—AGXT2—Metabolism—ERCC2—skin cancer	0.000207	0.00105	CbGpPWpGaD
Glycine—SHMT1—Disease—ERCC2—skin cancer	0.000202	0.00102	CbGpPWpGaD
Glycine—GPR18—Signaling by GPCR—NRAS—skin cancer	0.000189	0.000956	CbGpPWpGaD
Glycine—SHMT1—Disease—TERT—skin cancer	0.000189	0.000955	CbGpPWpGaD
Glycine—GRIN2C—Neuronal System—HRAS—skin cancer	0.000179	0.000908	CbGpPWpGaD
Glycine—GRIN2A—Transmission across Chemical Synapses—HRAS—skin cancer	0.000179	0.000904	CbGpPWpGaD
Glycine—GPR18—Signaling Pathways—BRAF—skin cancer	0.000178	0.000899	CbGpPWpGaD
Glycine—GLYATL2—Metabolism—PTGS2—skin cancer	0.000172	0.000868	CbGpPWpGaD
Glycine—GLYATL1—Metabolism—PTGS2—skin cancer	0.000172	0.000868	CbGpPWpGaD
Glycine—GLYAT—Metabolism—PTGS2—skin cancer	0.000172	0.000868	CbGpPWpGaD
Glycine—GATM—Metabolism—PTGS2—skin cancer	0.000172	0.000868	CbGpPWpGaD
Glycine—SHMT1—Metabolism—ERCC2—skin cancer	0.000169	0.000853	CbGpPWpGaD
Glycine—GSS—Metabolism—ERCC2—skin cancer	0.000164	0.000832	CbGpPWpGaD
Glycine—BAAT—Metabolism—PTGS2—skin cancer	0.000164	0.000828	CbGpPWpGaD
Glycine—GPR18—Signaling by GPCR—KRAS—skin cancer	0.000163	0.000823	CbGpPWpGaD
Glycine—SHMT1—Disease—BRAF—skin cancer	0.00015	0.000756	CbGpPWpGaD
Glycine—AGXT—Metabolism—PTGS2—skin cancer	0.000146	0.000738	CbGpPWpGaD
Glycine—ALAS1—Metabolism—PTGS2—skin cancer	0.000141	0.000715	CbGpPWpGaD
Glycine—GPR18—Signaling by GPCR—HRAS—skin cancer	0.000138	0.0007	CbGpPWpGaD
Glycine—GRIN2A—Neuronal System—HRAS—skin cancer	0.000137	0.000693	CbGpPWpGaD
Glycine—GPR18—Signaling by GPCR—IL6—skin cancer	0.000132	0.00067	CbGpPWpGaD
Glycine—AGXT2—Metabolism—PTGS2—skin cancer	0.000124	0.000628	CbGpPWpGaD
Glycine—SHMT1—Disease—PTGS2—skin cancer	0.000121	0.000611	CbGpPWpGaD
Glycine—GPR18—Signaling Pathways—NRAS—skin cancer	0.000112	0.000565	CbGpPWpGaD
Glycine—SHMT1—Metabolism—PTGS2—skin cancer	0.000101	0.000512	CbGpPWpGaD
Glycine—GSS—Metabolism—PTGS2—skin cancer	9.86e-05	0.000499	CbGpPWpGaD
Glycine—GPR18—Signaling Pathways—KRAS—skin cancer	9.61e-05	0.000486	CbGpPWpGaD
Glycine—SHMT1—Disease—NRAS—skin cancer	9.4e-05	0.000475	CbGpPWpGaD
Glycine—GPR18—Signaling Pathways—TP53—skin cancer	8.54e-05	0.000432	CbGpPWpGaD
Glycine—GPR18—Signaling Pathways—HRAS—skin cancer	8.17e-05	0.000413	CbGpPWpGaD
Glycine—SHMT1—Disease—KRAS—skin cancer	8.09e-05	0.000409	CbGpPWpGaD
Glycine—GPR18—Signaling Pathways—IL6—skin cancer	7.82e-05	0.000395	CbGpPWpGaD
Glycine—SHMT1—Disease—HRAS—skin cancer	6.88e-05	0.000348	CbGpPWpGaD
Glycine—SHMT1—Disease—IL6—skin cancer	6.58e-05	0.000333	CbGpPWpGaD
